These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 25870068)

  • 1. Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis.
    Alsultan A; An G; Peloquin CA
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3800-7. PubMed ID: 25870068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients.
    van den Elsen SHJ; Sturkenboom MGG; Van't Boveneind-Vrubleuskaya N; Skrahina A; van der Werf TS; Heysell SK; Mpagama S; Migliori GB; Peloquin CA; Touw DJ; Alffenaar JC
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30373800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of oral levofloxacin in healthy volunteers and dosing optimization for multidrug-resistant tuberculosis therapy.
    Boonpeng A; Jaruratanasirikul S; Wattanavijitkul T; Nawakitrangsan M; Samaeng M
    Biopharm Drug Dispos; 2021 Jul; 42(7):329-337. PubMed ID: 34117648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB.
    Ghimire S; Van't Boveneind-Vrubleuskaya N; Akkerman OW; de Lange WC; van Soolingen D; Kosterink JG; van der Werf TS; Wilffert B; Touw DJ; Alffenaar JW
    J Antimicrob Chemother; 2016 Oct; 71(10):2691-703. PubMed ID: 27231277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients.
    Van't Boveneind-Vrubleuskaya N; Seuruk T; van Hateren K; van der Laan T; Kosterink JGW; van der Werf TS; van Soolingen D; van den Hof S; Skrahina A; Alffenaar JC
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28507117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.
    Bouton TC; Phillips PPJ; Mitnick CD; Peloquin CA; Eisenach K; Patientia RF; Lecca L; Gotuzzo E; Gandhi NR; Butler D; Diacon AH; Martel B; Santillan J; Hunt KR; Vargas D; von Groote-Bidlingmaier F; Seas C; Dianis N; Moreno-Martinez A; Horsburgh CR
    Trials; 2017 Nov; 18(1):563. PubMed ID: 29178937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis.
    van Rijn SP; Zuur MA; van Altena R; Akkerman OW; Proost JH; de Lange WC; Kerstjens HA; Touw DJ; van der Werf TS; Kosterink JG; Alffenaar JW
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis.
    Deshpande D; Pasipanodya JG; Mpagama SG; Bendet P; Srivastava S; Koeuth T; Lee PS; Bhavnani SM; Ambrose PG; Thwaites G; Heysell SK; Gumbo T
    Clin Infect Dis; 2018 Nov; 67(suppl_3):S293-S302. PubMed ID: 30496461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.
    Mpagama SG; Ndusilo N; Stroup S; Kumburu H; Peloquin CA; Gratz J; Houpt ER; Kibiki GS; Heysell SK
    Antimicrob Agents Chemother; 2014; 58(2):782-8. PubMed ID: 24247125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection.
    Al-Shaer MH; Alghamdi WA; Alsultan A; An G; Ahmed S; Alkabab Y; Banu S; Barbakadze K; Houpt E; Kipiani M; Mikiashvili L; Cegielski JP; Kempker RR; Heysell SK; Peloquin CA
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations.
    Sarathy J; Blanc L; Alvarez-Cabrera N; O'Brien P; Dias-Freedman I; Mina M; Zimmerman M; Kaya F; Ho Liang HP; Prideaux B; Dietzold J; Salgame P; Savic RM; Linderman J; Kirschner D; Pienaar E; Dartois V
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30803965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis.
    Deshpande D; Pasipanodya JG; Srivastava S; Bendet P; Koeuth T; Bhavnani SM; Ambrose PG; Smythe W; McIlleron H; Thwaites G; Gumusboga M; Van Deun A; Gumbo T
    Clin Infect Dis; 2018 Nov; 67(suppl_3):S274-S283. PubMed ID: 30496459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis.
    Denti P; Garcia-Prats AJ; Draper HR; Wiesner L; Winckler J; Thee S; Dooley KE; Savic RM; McIlleron HM; Schaaf HS; Hesseling AC
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.
    Deshpande D; Pasipanodya JG; Mpagama SG; Srivastava S; Bendet P; Koeuth T; Lee PS; Heysell SK; Gumbo T
    Clin Infect Dis; 2018 Nov; 67(suppl_3):S317-S326. PubMed ID: 30496457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens.
    Yew WW; Chan CK; Chau CH; Tam CM; Leung CC; Wong PC; Lee J
    Chest; 2000 Mar; 117(3):744-51. PubMed ID: 10713001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands.
    Mase SR; Jereb JA; Gonzalez D; Martin F; Daley CL; Fred D; Loeffler AM; Menon LR; Bamrah Morris S; Brostrom R; Chorba T; Peloquin CA
    Pediatr Infect Dis J; 2016 Apr; 35(4):414-21. PubMed ID: 26658531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic-Pharmacodynamic Determinants of Clinical Outcomes for Rifampin-Resistant Tuberculosis: A Multisite Prospective Cohort Study.
    Heysell SK; Mpagama SG; Ogarkov OB; Conaway M; Ahmed S; Zhdanova S; Pholwat S; Alshaer MH; Chongolo AM; Mujaga B; Sariko M; Saba S; Rahman SMM; Uddin MKM; Suzdalnitsky A; Moiseeva E; Zorkaltseva E; Koshcheyev M; Vitko S; Mmbaga BT; Kibiki GS; Pasipanodya JG; Peloquin CA; Banu S; Houpt ER
    Clin Infect Dis; 2023 Feb; 76(3):497-505. PubMed ID: 35731948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Outcomes with Fluoroquinolone-Containing Regimens for Isoniazid-Resistant Pulmonary Tuberculosis.
    Lee H; Jeong BH; Park HY; Jeon K; Huh HJ; Lee NY; Koh WJ
    Antimicrob Agents Chemother; 2016 Jan; 60(1):471-7. PubMed ID: 26525801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Saliva as a Potential Alternative Sampling Matrix for Therapeutic Drug Monitoring of Levofloxacin in Patients with Multidrug-Resistant Tuberculosis.
    Ghimire S; Maharjan B; Jongedijk EM; Kosterink JGW; Ghimire GR; Touw DJ; van der Werf TS; Shrestha B; Alffenaar JC
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30782999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.